Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gynecology

  Free Subscription

Articles published in
Ann Oncol
    August 2021
  1. SLAMON DJ, Neven P, Chia S, Jerusalem G, et al
    Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [An
    Ann Oncol. 2021 Aug 16. pii: S0923-7534(21)02209.
    >> Share

  2. MARTIN JE, Khalife-Hachem S, Grinda T, Kfoury M, et al
    Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
    Ann Oncol. 2021;32:1046-1048.
    >> Share

    July 2021
  3. COLOMBO N, Ledermann JA
    Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.
    Ann Oncol. 2021 Jul 14. pii: S0923-7534(21)02182.
    >> Share

  4. DI VINCENZO A, Andrisani A, Vettor R, Rossato M, et al
    Estrogen and COVID-19: friend or foe?
    Ann Oncol. 2021;32:933-934.
    >> Share

    June 2021
  5. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
    Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].
    Ann Oncol. 2021 Jun 2. pii: S0923-7534(21)02020.
    >> Share

    May 2021
  6. SLAMON DJ, Neven P, Chia S, Jerusalem G, et al
    Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.
    Ann Oncol. 2021 May 15. pii: S0923-7534(21)01553.
    >> Share

    April 2021
  7. BELLONE S, Roque DM, Siegel ER, Buza N, et al
    A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
    Ann Oncol. 2021 Apr 28. pii: S0923-7534(21)01170.
    >> Share

    March 2021
  8. BAERT T, Ferrero A, Sehouli J, O Donnell DM, et al
    The Systemic Treatment of Recurrent Ovarian Cancer revisited.
    Ann Oncol. 2021 Mar 3. pii: S0923-7534(21)00155.
    >> Share

  9. MOORE KN, Oza AM, Colombo N, Oaknin A, et al
    Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
    Ann Oncol. 2021 Mar 2. pii: S0923-7534(21)00157.
    >> Share

    January 2021
  10. MONTOPOLI M, Zorzi M, Cocetta V, Prayer-Galetti T, et al
    Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy.
    Ann Oncol. 2021 Jan 29. pii: S0923-7534(21)00097.
    >> Share

  11. WU XH, Zhu JQ, Yin RT, Yang JX, et al
    Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial.
    Ann Oncol. 2021 Jan 13. pii: S0923-7534(21)00008.
    >> Share

  12. TOBALINA L, Armenia J, Irving E, O'Connor MJ, et al
    A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
    Ann Oncol. 2021;32:103-112.
    >> Share

    December 2020
  13. PILIE PG, George A, Yap TA
    Patient selection biomarker strategies for PARP inhibitor therapy.
    Ann Oncol. 2020;31:1603-1605.
    >> Share

    September 2020
  14. MILLER RE, Leary A, Scott CL, Serra V, et al
    ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    Ann Oncol. 2020 Sep 28. pii: S0923-7534(20)42164.
    >> Share

  15. LAMBERTINI M, Peccatori FA, Demeestere I, Amant F, et al
    Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines.
    Ann Oncol. 2020 Sep 16. pii: S0923-7534(20)42448.
    >> Share

    July 2020
  16. LUEN SJ, Asher R, Lee CK, Savas P, et al
    Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
    Ann Oncol. 2020 Jul 8. pii: S0923-7534(20)39934.
    >> Share

    June 2020
  17. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
    The forefront of ovarian cancer therapy: update on PARP inhibitors.
    Ann Oncol. 2020 Jun 19. pii: S0923-7534(20)39891.
    >> Share

    May 2020
  18. MILLSTEIN J, Budden T, Goode EL, Anglesio MS, et al
    Prognostic gene expression signature for high-grade serous ovarian cancer.
    Ann Oncol. 2020 May 27. pii: S0923-7534(20)39841.
    >> Share

    March 2020
  19. BOLZE PA, You B, Lotz JP, Massardier J, et al
    Successful pregnancy in a cancer patient previously cured of a gestational trophoblastic tumor by immunotherapy.
    Ann Oncol. 2020 Mar 11. pii: S0923-7534(20)36076.
    >> Share

    February 2020
  20. WAKS AG, Cohen O, Kochupurakkal B, Kim D, et al
    Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055.
    >> Share

  21. KALLIALA I, Athanasiou A, Veroniki AA, Salanti G, et al
    Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature.
    Ann Oncol. 2020;31:213-227.
    >> Share

    October 2019
  22. AMANT F, Berveiller P, Boere IA, Cardonick E, et al
    Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting.
    Ann Oncol. 2019;30:1601-1612.
    >> Share

    August 2019
  23. AMANT F, Berveiller P, Boere I, Cardonick E, et al
    Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting.
    Ann Oncol. 2019 Aug 21. pii: 5552554. doi: 10.1093.
    >> Share

    July 2019
  24. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
    Ann Oncol. 2019;30:1080-1087.
    >> Share

  25. GAILLARD SL, Coleman RL
    Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
    Ann Oncol. 2019;30:1025-1028.
    >> Share

    May 2019
  26. GAILLARD SL, Coleman RL
    Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
    Ann Oncol. 2019 May 21. pii: 5492551. doi: 10.1093.
    >> Share

  27. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    Reply to the Letter to the Editor: "European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al." by J. Marsden, H. Hamoda, On behalf of the British Menopause Society Medical Advisory Council.
    Ann Oncol. 2019 May 9. pii: 5487409. doi: 10.1093.
    >> Share

  28. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.
    Ann Oncol. 2019 May 2. pii: 5482567. doi: 10.1093.
    >> Share

  29. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
    ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger.
    Ann Oncol. 2019 May 2. pii: 5482247. doi: 10.1093.
    >> Share

  30. JOLY F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, et al
    Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.
    Ann Oncol. 2019;30:845-852.
    >> Share

  31. BUECHEL M, Herzog TJ, Westin SN, Coleman RL, et al
    Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
    Ann Oncol. 2019;30:721-732.
    >> Share

  32. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
    ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
    Ann Oncol. 2019;30:672-705.
    >> Share

    April 2019
  33. LORUSSO D, Pignata S, Gonzalez-Martin A
    Chemotherapy-free treatments: are we ready for prime time?
    Ann Oncol. 2019;30:497-498.
    >> Share

  34. LIU JF, Barry WT, Birrer M, Lee JM, et al
    Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Ann Oncol. 2019;30:551-557.
    >> Share

    March 2019
  35. BUECHEL M, Herzog TJ, Westin SN, Coleman RL, et al
    Treatment of Patients with Recurrent Epithelial Ovarian Cancer for Whom Platinum is Still an Option.
    Ann Oncol. 2019 Mar 18. pii: 5384492. doi: 10.1093.
    >> Share

  36. JOLY F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, et al
    Long-term fatigue and quality of life among epithelial ovarian cancer survivors: A GINECO case/control VIVROVAIRE I Study.
    Ann Oncol. 2019 Mar 9. pii: 5372686. doi: 10.1093.
    >> Share

    February 2019
  37. LIU JF, Barry WT, Birrer M, Lee JM, et al
    Overall survival and updated progression-free survival outcomes in a randomized phase 2 study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Ann Oncol. 2019 Feb 7. pii: 5308594. doi: 10.1093.
    >> Share

  38. TRIFANESCU OG, Topliceanu F, Gusoiu BA, Gales LN, et al
    24PReactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.
    Ann Oncol. 2019;30.
    >> Share

  39. WEBB PM, Na R, Weiderpass E, Adami HO, et al
    Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium.
    Ann Oncol. 2019;30:310-316.
    >> Share

  40. HUANG T, Tworoger SS, Willett WC, Stampfer MJ, et al
    Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.
    Ann Oncol. 2019;30:303-309.
    >> Share

  41. TRIFANESCU OG, Topliceanu F, Gusoiu BA, Gales LN, et al
    Reactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.
    Ann Oncol. 2019;30 Suppl 1:i8-i9.
    >> Share

  42. STONE A, Gebski V, Davidson R, Bloomfield R, et al
    Exaggeration of PFS by blinded, independent, central review (BICR).
    Ann Oncol. 2019;30:332-338.
    >> Share

    December 2018
  43. HUANG T, Tworoger SS, Willett WC, Stampfer MJ, et al
    Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.
    Ann Oncol. 2018 Dec 21. pii: 5255827. doi: 10.1093.
    >> Share

  44. WEBB PM, Na R, Weiderpass E, Adami HO, et al
    Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium.
    Ann Oncol. 2018 Dec 19. pii: 5253175. doi: 10.1093.
    >> Share

    October 2018
  45. LEDERMANN JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, et al
    Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018;29.
    >> Share

    July 2018
  46. BASU B, Krebs MG, Sundar R, Wilson RH, et al
    Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
    Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
    >> Share

    June 2018
  47. BRUSSELAERS N, Tamimi RM, Konings P, Rosner B, et al
    Different menopausal hormone regimens and risk of breast cancer.
    Ann Oncol. 2018 Jun 18. pii: 5039890. doi: 10.1093.
    >> Share

  48. FOTOPOULOU C, Sehouli J, Mahner S, Harter P, et al
    HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?
    Ann Oncol. 2018 Jun 4. pii: 5032848. doi: 10.1093.
    >> Share

    May 2018
  49. MIRZA MR, Pignata S, Ledermann JA
    Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Ann Oncol. 2018 May 10. pii: 4994787. doi: 10.1093.
    >> Share

  50. MARTH C, Landoni F, Mahner S, McCormack M, et al
    Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018 May 5. pii: 4993205. doi: 10.1093.
    >> Share

    April 2018
  51. RAY-COQUARD I, Morice P, Lorusso D, Prat J, et al
    Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018 Apr 25. pii: 4983953. doi: 10.1093.
    >> Share

  52. CREUTZBERG CL, Bosse T
    Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?
    Ann Oncol. 2018 Apr 14. pii: 4970554. doi: 10.1093.
    >> Share

    March 2018
  53. TAO MH, Chen S, Freudenheim JL, Cauley JA, et al
    Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
    Ann Oncol. 2018 Mar 29. pii: 4956655. doi: 10.1093.
    >> Share

    February 2018
  54. PICCIRILLO MC, Scambia G, Bologna A, Signoriello S, et al
    Quality of life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
    Ann Oncol. 2018 Feb 16. pii: 4864364. doi: 10.1093.
    >> Share

  55. BIRKBAK NJ, Li Y, Pathania S, Greene-Colozzi A, et al
    Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers.
    Ann Oncol. 2018 Feb 14. pii: 4857262. doi: 10.1093.
    >> Share

  56. KOMMOSS S, McConechy MK, Kommoss F, Leung S, et al
    Final Validation of the ProMisE Molecular Classifier for Endometrial Carcinoma in a Large Population-based Case Series.
    Ann Oncol. 2018 Feb 7. pii: 4844033. doi: 10.1093.
    >> Share

  57. OSKAY-OZCELIK G, Alavi S, Richter R, Keller M, et al
    EXPRESSION III: Patient s Expectations and Preferences regarding Physician-Patient Relationship and Clinical Management. Results of the International NOGGO/ENGOT-ov4-GCIG study in 1,830 Ovarian Cancer Patients from European countries.
    Ann Oncol. 2018 Feb 5. pii: 4838337. doi: 10.1093.
    >> Share

  58. BANERJEE S, Oza AM, Birrer MJ, Hamilton EP, et al
    Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Ann Oncol. 2018 Feb 1. pii: 4833235. doi: 10.1093.
    >> Share

    December 2017
  59. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    >> Share

  60. FRIEDLANDER M, Rau J, Lee CK, Meier W, et al
    Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenan
    Ann Oncol. 2017 Dec 18. pii: 4756055. doi: 10.1093.
    >> Share

    November 2017
  61. DE BOER SM, Wortman BG, Bosse T, Powell ME, et al
    Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.
    Ann Oncol. 2017 Nov 27. pii: 4668721. doi: 10.1093.
    >> Share

  62. PROVENCHER DM, Gallagher CJ, Parulekar WR, Ledermann JA, et al
    OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
    Ann Oncol. 2017 Nov 23. pii: 4654091. doi: 10.1093.
    >> Share

  63. OKTAY K, Taylan E, Rodriguez-Wallberg KA, Bedoschi G, et al
    Goserelin Does Not Preserve Ovarian Function Against Chemotherapy-Induced Damage.
    Ann Oncol. 2017 Nov 3. doi: 10.1093.
    >> Share

  64. LEDERMANN JA
    Front-line therapy of advanced ovarian cancer: new approaches.
    Ann Oncol. 2017;28.
    >> Share

  65. MONK BJ, Chan JK
    Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
    Ann Oncol. 2017;28.
    >> Share

  66. MARTH C, Reimer D, Zeimet AG
    Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
    Ann Oncol. 2017;28.
    >> Share

  67. BOOKMAN MA, Okamoto A, Stuart G, Yanaihara N, et al
    Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
    Ann Oncol. 2017;28.
    >> Share

  68. BRAND AH, DiSilvestro PA, Sehouli J, Berek JS, et al
    Cytoreductive surgery for ovarian cancer: quality assessment.
    Ann Oncol. 2017;28.
    >> Share

  69. CHRISTIE EL, Bowtell DDL
    Acquired chemotherapy resistance in ovarian cancer.
    Ann Oncol. 2017;28.
    >> Share

  70. DUSKA LR, Kohn EC
    The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications.
    Ann Oncol. 2017;28.
    >> Share

  71. ODUNSI K
    Immunotherapy in ovarian cancer.
    Ann Oncol. 2017;28.
    >> Share

  72. EISENHAUER EA
    Real-world evidence in the treatment of ovarian cancer.
    Ann Oncol. 2017;28.
    >> Share

  73. PUJADE-LAURAINE E
    New treatments in ovarian cancer.
    Ann Oncol. 2017;28.
    >> Share

  74. PIGNATA S, C Cecere S, Du Bois A, Harter P, et al
    Treatment of recurrent ovarian cancer.
    Ann Oncol. 2017;28.
    >> Share

  75. PARK SB, Kwok JB, Asher R, Lee CK, et al
    Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
    Ann Oncol. 2017;28:2733-2740.
    >> Share

    October 2017
  76. NABIEVA N, Kellner S, Fehm T, Haberle L, et al
    Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    >> Share

    September 2017
  77. LORUSSO D, Pignata S
    Role of adjuvant chemotherapy in early stage endometrioid and clear cell ovarian cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    >> Share

  78. OSELEDCHYK A, Leitao MM Jr, Konner J, O'Cearbhaill RE, et al
    Adjuvant Chemotherapy in Patients with Stage I Endometrioid or Clear Cell Ovarian Cancer in the Platinum Era: A Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    >> Share

  79. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    >> Share

    March 2017
  80. THAKER PH, Salani R, Brady WE, Lankes HA, et al
    A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
    Ann Oncol. 2017;28:505-511.
    >> Share

    April 2016
  81. DI MAIO M, Perrone F
    Lessons from clinical trials on quality of life assessment in ovarian cancer trials.
    Ann Oncol. 2016.
    >> Share

  82. FRIEDLANDER M, Mercieca-Bebber RL, King MT
    Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.
    Ann Oncol. 2016;27 Suppl 1:i66-i71.
    >> Share

  83. PUJADE-LAURAINE E, Combe P
    Recurrent ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i63-i65.
    >> Share

  84. BOOKMAN MA
    Optimal primary therapy of ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i58-i62.
    >> Share

  85. LEDERMANN JA
    PARP inhibitors in ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i40-i44.
    >> Share

  86. KRZYSTYNIAK J, Ceppi L, Dizon DS, Birrer MJ, et al
    Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i4-i10.
    >> Share

  87. MONK BJ, Minion LE, Coleman RL
    Anti-angiogenic agents in ovarian cancer: past, present, and future.
    Ann Oncol. 2016;27 Suppl 1:i33-i39.
    >> Share

  88. MAHNER S, Trillsch F, Chi D, Harter P, et al
    Neoadjuvant chemotherapy in ovarian cancer revisited.
    Ann Oncol. 2016;27 Suppl 1:i30-i32.
    >> Share

  89. REYNERS AK, Broekman KE, Glaudemans AW, Brouwers AH, et al
    Molecular imaging in ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i23-i29.
    >> Share

  90. COUKOS G, Tanyi J, Kandalaft LE
    Opportunities in immunotherapy of ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i11-i15.
    >> Share

  91. KAYE SB
    Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
    Ann Oncol. 2016;27 Suppl 1:i1-i3.
    >> Share

  92. POVEDA A, Romero I
    Advanced ovarian cancer: 20 years of ovarian cancer treatment.
    Ann Oncol. 2016;27 Suppl 1:i72-i73.
    >> Share

    March 2016
  93. MOSCHETTA M, George A, Kaye SB, Banerjee S, et al
    BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    Ann Oncol. 2016.
    >> Share

  94. FUJIWARA K, Monk BJ, Lhomme C, Coleman RL, et al
    Health-related Quality of Life in Women With Recurrent Ovarian Cancer Receiving Paclitaxel Plus Trebananib or Placebo (TRINOVA-1).
    Ann Oncol. 2016.
    >> Share

  95. MATULONIS UA, Penson RT, Domchek SM, Kaufman B, et al
    Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety.
    Ann Oncol. 2016.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016